Indications to teriparatide treatment in patients with osteoporosis

摘要

Study questionTo prevent osteoporotic fracture occurrence, the antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents. Their actions include reduction of bone turnover, decrease of further bone loss, and thereby a more homogenous mean degree of mineralisation. The recombinant amino-termi-nal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent, which reduces fracture risk by stimulating the deposition of new bone mass and by improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis.